Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Rationale and Use of BTK Inhibitors as Initial Treatment for CLL

August 23rd 2021

A comprehensive breakdown of the rationale behind targeting BTK signaling in CLL, as well as considerations for clinical experience with the available BTK inhibitors.

The Evolution of CLL Treatment

August 23rd 2021

Tara Graff, DO, MS, outlines the current treatment paradigm for chronic lymphocytic leukemia by discussing the use of novel agents, molecular testing, and risk stratification.

Long-term Follow-up Solidifies Role of Fixed-duration Venetoclax Plus Rituximab in Relapsed/Refractory CLL

August 17th 2021

Updated efficacy outcomes of the phase 3 MURANO trial demonstrated that fixed-duration venetoclax plus rituximab is an effective treatment approach for patients with relapsed/refractory chronic lymphocytic leukemia and did not compromise response to subsequent therapy or overall survival.

CLL: GLOW Trial Overview

August 17th 2021

Steven Coutre, MD, provides an overview of the phase 3 GLOW trial, as well as other novel and emerging combinations for the treatment of chronic lymphocytic leukemia (CLL).

CLL Therapies: Novel Combinations

August 17th 2021

John Allen, MD, provides an overview of data looking at emerging combinations as initial therapy for chronic lymphocytic leukemia (CLL).

Frontline Targeted Therapy in CLL: Tolerability and Toxicity Management

August 16th 2021

A comprehensive breakdown of the tolerability of frontline targeted therapies used to manage chronic lymphocytic leukemia and toxicity management.

Moving the Dial on CLL Management: Sequencing Strategies and Unmet Needs

August 16th 2021

Before addressing unmet needs in the management of CLL, Brad S. Kahl, MD, outlines optimal sequencing strategies in the current treatment paradigm.

Optimal Toxicity Management With BTK Inhibitors in CLL

August 16th 2021

Brad S. Kahl, MD, shares practical advice on the management of BTK inhibitor–related toxicity in patients with chronic lymphocytic leukemia.

Head-to-Head Analysis of Acalabrutinib Vs Ibrutinib in Previously Treated CLL

August 16th 2021

Considerations for the head-to-head data out of ASCO 2021 comparing acalabrutinib and ibrutinib in previously treated chronic lymphocytic leukemia.

4-Year Follow-up Data From ELEVATE-TN: Frontline Acalabrutinib in CLL

August 16th 2021

Insight on the 4-year follow-up data from ELEVATE-TN and the frontline use of acalabrutinib, with or without anti-CD20 therapy, in patients with CLL.

Frontline BTK Inhibition in CLL: 7-Year Follow-up Data From RESONATE-2

August 16th 2021

Brad S. Kahl, MD, reflects on the 7-year follow-up data from the RESONATE-2 trial, which tested ibrutinib as frontline therapy in patients with CLL.

Revolutionizing the Management of Chronic Lymphocytic Leukemia

August 16th 2021

A comprehensive analysis of the CLL treatment landscape, including available agents, risk stratification, and triggers to initiate therapy.

Optimizing the Frontline Management of High-Risk CLL

August 16th 2021

After determining the parameters of high-risk CLL, key opinion leaders clarify optimal frontline management strategies.

Dr. Danilov on the Efficacy of the Combination Zandelisib and Zanubrutinib in R/R B-Cell Malignancies

August 13th 2021

Alexey V. Danilov, MD, PhD, discusses the efficacy seen in the ongoing phase 1b study examining the combination of zandelisib and zanubrutinib in patients with relapsed/refractory B-cell malignancies.

BTK Inhibitors Represent the Preferred Frontline Regimen in CLL

August 13th 2021

The majority of patients with newly diagnosed chronic lymphocytic leukemia have better outcomes with BTK inhibitors compared with standard chemoimmunotherapy, making them the logical choice for frontline therapy.

Acalabrutinib Induces Durable Disease Control in Frontline CLL at 4 Years

August 11th 2021

Acalabrutinib, alone or in combination with obinutuzumab, demonstrated superior efficacy and an acceptable safety profile in patients with treatment-naïve chronic lymphocytic leukemia.

Dr. Thompson on the Evolving Role of MRD Testing in CLL

August 11th 2021

Meghan Thompson, MD, discusses the evolving role of minimal residual disease testing in chronic lymphocytic leukemia.

Dr. Roeker on the Rationale for BTK/Venetoclax Combos in CLL

August 10th 2021

Lindsey Roeker, MD, discusses the rationale for combining venetoclax with BTK inhibitors for use in patients with chronic lymphocytic leukemia.

Fixed-Duration Ibrutinib/Venetoclax Provides Deep, Durable Responses in Frontline CLL/SLL

August 10th 2021

A fixed duration of ibrutinib plus venetoclax has demonstrated durable efficacy when used in the frontline treatment of patients with chronic lymphocytic leukemia and small lymphocytic lymphoma (SLL).

BCL2 Inhibitors in Previously Untreated CLL

August 10th 2021

Experts discuss the optimal approach for choosing between a Bruton tyrosine kinase (BTK) inhibitor–based therapy vs a BCL2 inhibitor–based regimen for frontline chronic lymphocytic leukemia (CLL) therapy.